Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher Clostridioides difficile infection rate.

Although prior PPI use might not have significant impact on clinical course and mortality of SARS-CoV-2 infection, it may predispose development of complications like higher occurrence of Cdiff, and thus substantially impact the course of treatment.